New drug combo targets tough breast cancers in small trial

NCT ID NCT05810870

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose cancer has spread and is hard to treat.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHUVI - Complejo Hospitalario Universitario de Vigo

    Vigo, Pontevedra, 36312, Spain

  • Centro Oncológico de Galicia

    A Coruña, Galicia, 15009, Spain

  • Hospital Beata María Ana

    Madrid, Spain

  • Hospital Clínic i Provincial de Barcelona

    Barcelona, 08036, Spain

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitari Vall D'Hebron

    Barcelona, Spain

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada, Andalusia, 18016, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Andalusia, 41013, Spain

  • Hospital Universitario de Torrejón

    Torrejón de Ardoz, Madrid, 28850, Spain

  • Institut Català d' Oncologia L'Hospitalet (ICO)

    Barcelona, 08907, Spain

  • Instituto Valenciano de Oncología (IVO)

    Valencia, 46009, Spain

  • Onkologikoa

    Donostia / San Sebastian, Basque Country, 20014, Spain

Conditions

Explore the condition pages connected to this study.